Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Anteris Technologies GlobalASX:AVR 45 Equity-to-Asset is 0.95 as of Mar. 2026, which is 58% above its 10-year median of 0.60. GuruFocus rates ASX:AVR with a GF Score™ of 45/100. The stock has 5 warning signs investors should review. Among 852 Medical Devices & Instruments companies, Anteris Technologies Global ranks better than 98% on this metric.
The historical rank and industry rank for Anteris Technologies Global's Equity-to-Asset or its related term are showing as below:
ASX:AVR'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.4 Med: 0.6 Max: 0.95
Current: 0.95
During the past 13 years, the highest Equity to Asset Ratio of Anteris Technologies Global was 0.95. The lowest was -0.40. And the median was 0.60.
ASX:AVR's Equity-to-Asset is ranked better than 98% of 852
companies
in the Medical Devices & Instruments industry
Industry Median: 0.645
vs ASX:AVR: 0.95
Anteris Technologies Global (ASX:AVR) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Anteris Technologies Global Equity-to-Asset Related Terms
Anteris Technologies Global Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:AVR vs BVS, SIBN, INMD: Equity-to-Asset Comparison
For the Medical Devices subindustry, Anteris Technologies Global's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anteris Technologies Global Equity-to-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Anteris Technologies Global's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Anteris Technologies Global's Equity-to-Asset falls into.
Anteris Technologies Global Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Anteris Technologies Global's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anteris Technologies Global (ASX:AVR) has a Equity-to-Asset of 0.95 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Anteris Technologies Global and its competitors. This is 58% above median its historical median of 0.60. According to the industry distribution chart, Anteris Technologies Global ranks #17 out of 852 companies in the Medical Devices & Instruments industry, placing it in the top 2%.
Is Anteris Technologies Global's Equity-to-Asset too high?
Anteris Technologies Global's current Equity-to-Asset of 0.95 is 58% above median its 10-year median of 0.60. The Medical Devices & Instruments industry median Equity-to-Asset is 0.65. Anteris Technologies Global's value of 0.95 is 47.3% above this industry median. Based on the distribution chart, Anteris Technologies Global ranks #17 out of 852 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Anteris Technologies Global has a GF Score™ of 45/100, reflecting its overall financial health beyond just this single metric.
How does Anteris Technologies Global's Equity-to-Asset compare to BVS and SIBN?
According to the Medical Devices & Instruments industry distribution chart, Anteris Technologies Global ranks #17 out of 852 companies for Equity-to-Asset. This places Anteris Technologies Global in the top 2% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.65. Anteris Technologies Global's value of 0.95 is 47.3% above this benchmark. While the company's 10-year median is 0.60 vs. the industry median of 0.65, Anteris Technologies Global has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Devices & Instruments company?
The median Equity-to-Asset among Medical Devices & Instruments companies is 0.65, based on 852 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Anteris Technologies Global's current Equity-to-Asset of 0.95 is 47.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Anteris Technologies Global and its competitors. For the Medical Devices & Instruments industry, the median Equity-to-Asset is 0.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anteris Technologies Global's current Equity-to-Asset is 0.95, which is 58% above median its own 10-year median of 0.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anteris Technologies Global stock overvalued right now?
Anteris Technologies Global (ASX:AVR) has a current Equity-to-Asset of 0.95. The current Equity-to-Asset is 0.95, which is 58% above median its 10-year median of 0.60 and 47.3% above the Medical Devices & Instruments industry median of 0.65. Anteris Technologies Global's overall GF Score™ is 45/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Anteris Technologies Global (ASX:AVR), the current Equity-to-Asset is 0.95 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anteris Technologies Global Corp is a structural heart company focused on advancing cardiac care through science-driven innovations aimed at restoring heart valve patients to healthy function. Its key product, the DurAVR Transcatheter Heart Valve (THV), was designed in partnership with interventional cardiologists and cardiac surgeons to treat Aortic Stenosis, a potentially life-threatening condition caused by narrowing of the aortic valve. The balloon-expandable DurAVR THV is a biomimetic valve designed to mimic the performance of a healthy human aortic valve and replicate normal aortic blood flow. The company operates in United States, Germany, Australia, Switzerland, and Sweden, with the majority of its revenue generated from the United States.
45GF Score
Get the complete analysis for ASX:AVR
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:AVR has been successfully added to your 
